MTOR and lymphoma: Target therapy, employing proteasome inhibitors, mTOR inhibitors, tyrosine kinase inhibitors, and histone deacetylase inhibitors (HDACi), plays an important role in clinical oncology [2], suggesting these pathways represent key signal transductions in lymphoma tumorigenesis.